膜杰作
Star Staining
抗体来源（Source）
Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) is a mouse monoclonal antibody produced from hybridoma.
应用（Application）
Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression).
克隆号（Clone）
Y45
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG1/kappa
特异性（Specificity）
Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.
免疫原（Immunogen）
Recombinant FMC63 scFv derived from HEK293 cells.
偶联（Conjugate）
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
同型对照（Isotype Control）
The Isotype control is sold separately and you can search for Cat. No. DNP-FM1A1 for product information.
推荐稀释比（Recommended Dilution）
1:50
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
活性（Bioactivity）-FACS
2e5 of Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) FITC-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Cat. No. FM3-FY45) and isotype control respectively. FITC signal was used to evaluate the binding activity (QC tested).
Protocol
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
